Chinese vaccine Sinopharm ineffective against some Omicron sub-variants: Study

Chinese vaccine Sinopharm ineffective against some Omicron sub-variants: Study

According to a small study published in The Lancet Infectious Diseases journal, two doses of Chinese Covid vaccine Sinopharm produced no or only minimally detectable neutralising activity against some Omicron sub-variants.

The study, led by Chinese researchers from Anhui Medical University in Hefei and the Beijing Institute of Microbiology and Epidemiology, revealed that a third booster dose partially restored the neutralising activity.

The study included 25 people who received two doses of the BBIBP-CorV vaccine. They discovered that neutralising activity against Omicron subvariants like BA.1, BA.2, BA.2.11, BA.2.12.1, BA.2.13, and BA.4/BA.5 “was not or only minimally detectable.”

Neutralizing activity against these subvariants was observed in 24-48 percent of people who received a BBIBP-CorV booster shot following a two-dose shot.

The neutralising activity of another Covid vaccine, ZF2001, developed by Anhui Zhifei Longcom, improved slightly to 30-53 percent among 30 participants who received a third dose.

Furthermore, the BA.2.12.1 subvariant showed significantly more resistance to a BBIBP-CorV booster than the BA.2 subvariant, and the BA.2.11, BA.2.12.1, and BA.2.13 subvariants showed significantly more resistance to a ZF2001 booster than the BA.2 subvariant.

Neutralizing activity against these subvariants was observed in 24-48 percent of people who received a BBIBP-CorV booster shot following a two-dose shot.

The neutralising activity of another Covid vaccine, ZF2001, developed by Anhui Zhifei Longcom, improved slightly to 30-53 percent among 30 participants who received a third dose.

Furthermore, the BA.2.12.1 subvariant showed significantly more resistance to a BBIBP-CorV booster than the BA.2 subvariant, and the BA.2.11, BA.2.12.1, and BA.2.13 subvariants showed significantly more resistance to a ZF2001 booster than the BA.2 subvariant.

Serum neutralising antibody titres against all pseudoviruses tested did not differ between those who received a BBIBP-CorV booster and those who received a ZF2001 booster.

BA.1 breakthrough infection affected approximately 18 people, while BA.2.2 breakthrough infection affected 15 people. Furthermore, the study found that neutralising antibodies against omicron subvariants that were above the detection limit accounted for 88-100 percent of infections.

By Brendan Taylor

Post a Comment

Previous Post Next Post

Advertisement

نموذج الاتصال